Utilizing a collaborative approach, the FNIH Biomarkers Consortium has brought together diabetes experts from the National Institutes of Health (NIH), Food and Drug Administration (FDA), leading academic institutions, the pharmaceutical industry, and non-profit sector to develop the project. Participating and funding organizations include: Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research and Development, LLC, Juvenile Diabetes Research Foundation, Merck, Sharp & Dohme Corp, Novartis Institutes for BioMedical Research, Inc., Pfizer, Inc., Sanofi-Aventis, and Takeda Global Research & Development Center, Inc.
"This public private partnership involves key stakeholders in the diabetes field in addressing a critical unmet medical need," Dr. Steven Paul, FNIH Board of Directors, Acting Chairman of the Biomarkers Consortium Executive Committee. "The validation of biomarkers to measure the progression of diabetes will greatly facilitate the development of better medicines to treat and potentially prevent this disease and its often disabling complications."
Ad Statistics
Times Displayed: 50697
Times Visited: 1465 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
For more information about this project please visit www.fnih.org.
The Request for Proposals (RFP) for the conduct of the first clinical study protocol with healthy volunteers can be found on biomarkersconsortium.org. Responses are due by May 31, 2011.
About the Foundation for the NIH
Established by the United States Congress to support the mission of the NIH-improving health through scientific discovery in the search for cures-the Foundation for the NIH is a leader in identifying and addressing complex scientific and health issues. The Foundation is a non-profit, 501(c)(3) charitable organization that raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities. For additional information about the Foundation for the NIH, please visit www.fnih.org
About the Biomarkers Consortium
The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to develop, validate, and/or qualify biological markers (biomarkers) to speed the development of medicines and therapies for detection, prevention, diagnosis and treatment of disease and improve patient care. For additional information about the Biomarkers Consortium, please visit www.biomarkersconsortium.org.
Back to HCB News
